M1 protein, a major virulence factor of the leading invasive strain of group A Streptococcus, is sufficient to induce toxic-shock-like vascular leakage and tissue injury. These events are triggered by the formation of a complex between M1 and fibrinogen that, unlike M1 or fibrinogen alone, leads to neutrophil activation. Here we provide a structural explanation for the pathological properties of the complex formed between streptococcal M1 and human fibrinogen. A conformationally dynamic coiled-coil dimer of M1 was found to organize four fibrinogen molecules into a specific cross-like pattern. This pattern supported the construction of a supramolecular network that was required for neutrophil activation but was distinct from a fibrin clot. Disruption of this network into other supramolecular assemblies was not tolerated. These results have bearing on the pathophysiology of streptococcal toxic shock.
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The M protein 1 is the major surface-associated virulence factor of Streptococcus pyogenes (group A Streptococcus), a widespread bacterial pathogen that causes both mild infections and severe invasive diseases with high mortality rates (,30%), such as streptococcal toxic shock syndrome (STSS) 2 . Antigenic variation has resulted in .100 M protein types 3 but only a few are frequently associated with invasive disease, with the M1 type being the most prevalent 4 . Strains belonging to a globally disseminated subclone of the M1T1 serotype have been the leading cause of severe invasive group A Streptococcus infection worldwide for the past 30 years 5 . The M1 protein itself has proinflammatory properties and in animal models is sufficient to trigger vascular leakage and tissue injury similar to that observed in STSS [6] [7] [8] [9] . These pathological properties of M1 require its interaction with fibrinogen. The M1-fibrinogen complex binds b 2 integrins on neutrophils and triggers the release of heparin binding protein (HBP), a potent vasodilator 10 and a strong indicator of sepsis and circulatory failure in patients 11 . The M1-fibrinogen complex also activates platelets in an integrin-dependent manner 12 , leading to further activation of neutrophils as well as monocytes.
How the M1-fibrinogen complex causes neutrophil activation, when neither protein alone does 6, 8 , is not known. To address this issue, we determined the ,3.3 Å resolution crystal structure of an M1-fibrinogen complex containing the M1 fragment M1 BC1 (residues 132-263, ,17 kDa) and fibrinogen fragment D (FgD, ,86 kDa) 13, 14 (Supplementary Table 1 and Supplementary Figs 1 and 2 ). The M1 BC1 fragment contains the B repeats, which are sufficient to bind fibrinogen 8, 15 , and the S region, to which immunoglobulin G (IgG) molecules bind and enhance the release of HBP through FccRII 7 ; it also contains the first C repeat of M1. FgD, which comprises the majority of fibrinogen, is necessary and sufficient to bind M1 (ref. 16 ). The final model consists of M1 BC1 residues 132-238, the register of which was separately determined using anomalous scattering (see Methods); all but the first five residues of the C repeats were apparently removed by proteolysis. The entirety of FgD, as seen in the crystal structure of the unbound form 13, 14 , was visible except for several residues at either end. Whereas residues of M1 BC1 distal to the interface with FgD were often in incomplete electron density, residues at the interface had well defined electron density, enabling specific intermolecular contacts to be discerned.
Cross-like pattern
The most striking aspect of the structure is the fact that M1 BC1 is surrounded by four FgD molecules in a cross-like pattern (Fig. 1) . Two pairs of FgD molecules (each ,130 Å long) lie roughly perpendicular to one other as well as to M1 BC1 (,160 Å long), which runs through the centre of the cross. FgD, as previously described 13 , consists of a parallel heterotrimeric (abc) a-helical coiled-coil connected to globular heads. M1 BC1 forms a parallel homodimeric a-helical coiled-coil throughout most of its length, including the B repeats that bind FgD. There are four B repeats in all, two per M1 chain, explaining the 2:4 M1 BC1 :FgD stoichiometry of this ,380-kDa complex. The upstream B repeats (B1) bind two FgD molecules that are oriented ,180u to one another due to the dyad symmetry of the M1 coiled coil, as do the downstream B repeats (B2). B1 and B2 are separated by 28 residues, roughly a one-quarter turn of the coiled-coil superhelix, meaning that the two pairs of FgD molecules are oriented ,90u to one another, giving rise to the cross-like pattern.
The four separate M1-FgD contact sites are nearly identical in structure, being predominantly polar and each having a small buried surface area of ,645 Å 2 ( Fig. 2a) . Residues in the B repeats from both helices of the coiled coil and every heptad position (that is, a-g) contribute to FgD binding (Fig. 2b) . Although the two B repeats are imperfect in sequence, the FgD-binding residues are identical between the two (Fig. 3) . For FgD, the coiled coils in the b and c chains are involved in binding M1, and contribute residues from the exposed b, c and e positions to the interface. The site at which M1 binds FgD is notably quite distant (,90 Å ) from the fibrinogen cC globular head, which has been shown to bind b 2 integrins 17 . The M1 S region is freely available to bind IgG molecules and thereby enhance HBP release.
Conformational dynamics
The heptad register in the B repeats observed here differs from that observed previously in the crystal structure of the M1 AB fragment (Figs 3a, b) . These two registers are related by a rotation of one helical face, or ,51.4u (Fig. 3c) . The ability of the B repeats to adopt these two competing registers is supported by coiled-coil propensity analysis 18 , (left) and B2 (right) in helical projection and FgD (cylinders, b-chain in blue and c in blue-green). Blue dotted lines connect residues making polar contacts, and grey and green arcs correspond to M1 residues making van der Waals contacts to fibrinogen c 108 and 109, respectively.
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which indicates that both registers 1 and 2 are embedded within the B repeats as short interspersed stretches ( Supplementary Fig. 3) . Surprisingly, residues that bind fibrinogen have a preference for register 1, which is incapable of binding fibrinogen, but are surrounded by residues that have a preference for register 2, the fibrinogen-binding register. In addition to these two registers being alternately sampled by the B repeats, a splayed conformation probably exists, as suggested by the dynamic dissociation and reassociation of M1 chains 8 . Presumably the splayed conformation enables transitions between registers 1 and 2, the latter being stabilized by fibrinogen binding.
To test experimentally for the presence of conformational dynamics, we stabilized register 1 in the B repeats without altering fibrinogenbinding residues. We hypothesized that fibrinogen binding should be decreased through this process if register 1 were sampled, because M1 would be 'locked' in the non-binding register. The ideal coiled-coil residues Val and Leu were substituted at a and d positions, respectively, of register 1 in the B repeats 19, 20 , except at the six a and d positions involved in FgD binding ( Supplementary Fig. 4 ). Most notable among these six were Tyr 155 and Tyr 183, which are at core a positions in register 1 but at exposed e positions in register 2, from which they make p-cation interactions with FgD b169. This variant of M1, called M1*-revertant (M1*-R), is equivalent to the previously characterized M1* except with all the fibrinogen-binding residues present 8 . M1* was shown to be more stable than wild-type M1 but substantially diminished in FgD binding. We found that M1*-R, like M1*, was also greatly attenuated for FgD binding (Fig. 3d) , and that this attenuation was specific, as M1*-R maintained wild-type levels of interaction with IgG Fc fragments (Fig. 3e ). This latter interaction occurs through M1 protein regions outside the B repeats 8 . These mutational results support the conclusion that register 1, along with register 2, is sampled in the B repeats. Altogether our observations provide evidence for large conformational dynamics in the B repeats. What purpose these dynamics serve is unknown, but one possibility is that they are advantageous for group A Streptococcus immune evasion, in effect providing a 'moving target' for antibody recognition.
M1-fibrinogen network
To address the mechanism of neutrophil activation, we modelled fibrinogen and intact M1 in place of FgD and M1 BC1 ( Fig. 4 and Supplementary Movie 1), respectively. Importantly, because fibrinogen is a dimer (of abc heterotrimers), a fibrinogen molecule has two M1-binding sites as opposed to the single site in FgD. From this modelling emerged a non-clashing M1-fibrinogen network with fibrinogen acting as struts and M1 acting as joints. The two M1 molecules that bound an individual fibrinogen were tilted with respect to each other due to the inherent flexibility of fibrinogen 21 . This tilt gave the network three-dimensional character and meant that the network incorporated M1 molecules pointing in opposite directions. The variation in M1 directionality indicates that the network is formed by free M1 released from the bacterial surface by neutrophil proteases 6 , as opposed to M1 anchored unidirectionally by its carboxy terminus to RESEARCH ARTICLE the bacterial cell wall 22 . Consistent with this notion, the greater proportion of M1 in samples from STSS patients occurs as free released protein 7 . The structure of the M1-fibrinogen network indicated a mechanism for neutrophil activation. Previous work had shown that antibody crosslinking of b 2 integrin had the same effect on neutrophil activation as the M1-fibrinogen complex 6, 9, 23 , indicating that b 2 integrin clustering and avidity are involved in signalling by M1-fibrinogen. On the basis of these data, we surmised that the fibrinogen density induced by the M1-fibrinogen network was likely to be a critical factor for neutrophil activation. To test this model, we compared HBP release by neutrophils stimulated with various M1 deletion constructs. M1 in which either the upstream or downstream B repeat was deleted, DB1 and DB2, respectively, retained fibrinogen binding due to the continued presence of one of the B repeats (Fig. 5a) . However, as the modelling predicted, DB1 and DB2 formed fibres (Fig. 4d, e and Supplementary Fig. 5a ) rather than the networks formed by wild-type M1 (Fig. 4b, c) . Despite being able to bind fibrinogen, neither DB1 nor DB2 triggered release of HBP from neutrophils, which was in sharp contrast to wild-type M1 (Fig. 5b) . This result indicates that the M1-fibrinogen network rather than fibrinogen-binding itself is required for neutrophil activation. We also demonstrated that the addition of FgD, which is unable to support network formation because it has only one M1-binding site, blocks M1-mediated neutrophil activation (Fig. 5c) . Excess FgD was necessary in this experiment as binding of M1 to FgD is weaker than it is to fibrinogen 24 , the difference being explained by the high avidity between M1 and fibrinogen as compared to the weaker affinity between M1 and FgD.
As expected, deletion of both B repeats (DB1B2) resulted in no networks, no fibres, and no induction of HBP release ( Fig. 5b and Supplementary Fig. 5b ). However, DB1B2 retained a low level of fibrinogen binding (Fig. 5a) . On the basis of this and other evidence, we uncovered a cryptic fibrinogen-binding site in the A region. A molecular replacement solution of a low-resolution crystal (7.5 Å resolution limit) of the M1 A region bound to FgD (M1 A -FgD) confirmed the existence of this site. This solution revealed two molecules of FgD oriented 180u to one another and arranged perpendicularly to the A region, similar to the binding mode observed for each of the B repeats (Supplementary Fig. 6 ). Although the low resolution limited our abilities to discern A-region residues, it was apparent that the same FgD residues bound by the B repeats were bound by the A region. This indicated that A-region residues 106-119 are the likely fibrinogen-binding site (Supplementary Fig. 7 ), as this region has some sequence similarity to the B repeats, including a Tyr capable of forming a p-cation bond to FgD b169; tyrosines are otherwise rare in the M1 sequence. In line with observations for the B repeats, the A-region site would also require a ,51.4u rotation in helical register from the conformation observed in M1 AB (ref. 8) to bind fibrinogen. Deletion of this putative fibrinogen-binding site in the A region along with both B repeats completely abrogated fibrinogen binding (Fig. 5a,  D98DB1B2 ). Although we found that the A-region site was not required for network formation or for HBP release ( Fig. 5b, D98 ; see Supplementary Fig. 5c ), the possibility that this cryptic site has other functions related to fibrinogen binding (for example, evasion of phagocytosis) merits future exploration.
Lastly, we asked whether the density of the M1-fibrinogen network was consequential. To address this, we deleted the downstream B repeat (B2) and inserted it at the C terminus of M1, thereby increasing the spacing between the two B repeats (Fig. 5a) . Modelling predicted that a sparser network should be formed by this construct, called B2C. B2C bound FgD and formed networks, but notably, did not trigger release of HBP (Figs 4f, g and 5d) . We note that the resolution of the electron micrographs did not allow us to distinguish between M1-fibrinogen and B2C-fibrinogen networks, but our modelling strongly suggests that the difference in network density accounted for the lack of neutrophil activation.
Conclusions
We have shown that a key pro-inflammatory property of M1, as exemplified by the induction of neutrophil HBP release, is due to the organization of fibrinogen into a specific cross-like pattern that supports the formation of an M1-fibrinogen network. This process requires the presence of two appropriately spaced B repeats. Repeats are a common feature of M protein sequences, but whether other fibrinogen-binding M protein types with repeat sequences have similar pro-inflammatory capabilities is unknown and under investigation. Because disruption of the M1-fibrinogen network into fibres or sparse networks resulted in loss of neutrophil activation, we conclude that the density of fibrinogen in the network is the critical factor in neutrophil activation. An alternative model would require a conformational change in fibrinogen upon M1 binding, as has been suggested for the unmasking of a b 2 integrin-binding tail in the cC globular domain of fibrinogen 25 . This possibility cannot be excluded as the tail is absent in FgD, but it seems unlikely to us as the tail would be quite distant from M1 and no large conformational changes were evident in FgD to transmit a binding signal to the tail. Although the M1-fibrinogen network is distinct from a fibrin clot, these supramolecular assemblies both present high densities of integrin-binding sites, indicating that integrin clustering and avidity are conserved mechanisms for leukocyte activation. Interference with the M1-fibrinogen interaction visualized here represents a potential therapeutic target to ameliorate the severe outcomes of STSS.
METHODS SUMMARY
Preparation of M1 and FgD, fibrinogen binding assays, and HBP release assays were carried out as previously described 8 . Diffraction data from crystals of M1
BC1 -FgD and M1
A -FgD were processed using MOSFLM 26 or HKL2000 
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and phases were determined by molecular replacement using the program Phaser 28 (Novagen) . The M1 deletion mutants and B2C were generated using the QuickChange II Site-Directed mutagenesis kit (Stratagene), according to manufacturer's instructions, or by the mega-primer method 30 . All M1 protein constructs had a C-terminal His tag for purification purposes, except for M1 BC1 . Protein expression and purification. M1 protein constructs were expressed in Escherichia coli BL21 (DE3), which were grown in LB containing 34 mg ml 21 kanamycin at 37 uC until mid-logarithmic phase and then induced at room temperature with 1 mM isopropyl b-D-1-thiogalactopyranoside and grown further for 18 h. Bacteria were harvested by centrifugation and re-suspended in either 100 mM NaCl, 50 mM sodium phosphate buffer, pH 8 (SP) or 100 mM NaCl, 50 mM Tris, pH 8 (ST), both with protease inhibitors (Complete tablet, Roche), for biochemical analysis or crystallization experiments, respectively. Bacteria were lysed using an EmulsiFlex-C5 (Avestin). His-tagged M1 constructs were then purified as previously reported 8 . For M1 BC1 , which lacks a His tag, the lysate was heat denatured at 75 uC for 30 min, cooled on ice for 30 min, and clarified by centrifugation. Nucleic acids were removed by the addition of 0.5% polyethyleneimine and the resulting supernatant was then precipitated with 75% (NH 4 ) 2 SO 4 . Precipitated protein was re-suspended in either SP or ST and dialysed overnight in the same buffer. Proteins were then purified on a Q-Sepharose anion exchange column (GE-Healthcare). Selenomethionine incorporation into M1 BC1 was carried out as previously described 31 , and the purification was carried out as above except with the addition of 1 mM dithiothreitol throughout.
Fibrinogen fragment D (FgD) was purified from human fibrinogen as described previously 32 . Briefly, human fibrinogen (Calbiochem) was trypsinized overnight in 150 mM NaCl, 5 mM CaCl 2 , 50 mM imidazole, pH 7 and purified on a Gly-Pro-Arg column equilibrated with the same buffer. The protein was eluted from the column with 1 M NaBr, 0.05 M NaOAc, pH 5. FgD was evident in initial electron density maps, with sufficient side-chain density for a tentative register to be assigned. The register was verified by independent means as follows. Ile 148 in M1
BC1 was substituted with methionine, and the resulting mutant protein was biosynthetically labelled with selenomethionine and crystallized in complex with FgD, as above. A highly redundant (1,080u) data set at the selenium anomalous absorption peak (0.9795 Å wavelength) was recorded at the APS (23-ID-D) to increase the signal to noise ratio. Data were processed using HKL2000 27 . A difference anomalous map was calculated using FFT 33 , and two anomalous peaks were located, resulting in the unambiguous location of residue 148 on each chain of the M1 BC1 coiled coil ( Supplementary Fig. 2 ). The entirety of M1 BC1 visible in the crystal structure was a-helical, and thus specification of the position of residue 148 enabled assignment of the remaining residues.
Refinement of the M1 BC1 -FgD model was performed using CNS 35 and Refmac 33 . All B-factors were initially set to 90 Å 2 and subsequently refined as side-chain and main-chain groups using bgroup from CNS 36 . Four-fold noncrystallographic symmetry (NCS) restraints were applied to FgD (medium restraints for the main chain and loose restraints for the side chain); each of the three chains of the fibrinogen abc heterotrimer formed a separate NCS group. The model was then refined using Refmac5, with five alternating macro-cycles of model building and refinement. Model building was guided by inspection of s A -weighted 2F o 2 F c and F o 2 F c omit maps 37 , and was carried out using COOT 38 . Side chains were modelled as preferred rotamers. Each refinement macro-cycle consisted of 10 micro-cycles of maximum likelihood restrained refinement using standard parameters, except for the following adjustments. Owing to the moderate resolution of the data, a weighting term of 0.01 was used to favour geometric restraints, and an overall temperature factor model and a Babinet scaling model were used 34 . Structure validation was performed using Procheck 39 and Molprobity 40 . In the final M1 BC1 -FgD model, 97.8% and 99.3% of residues were in allowed and generously allowed Ramachandran regions, respectively. The final map had correlation coefficients of 0.90 and 0.68 for the main chain and side chains, respectively, as calculated with OVERLAPMAP 33 . The Molprobity 40 clash score was 24.63 (89th percentile) and overall score was 3.18 (77th percentile).
Molecular figures were generated with PyMol (http://pymol.sourceforge.net). Modelling of M1-fibrinogen. The A region of intact M1 was modelled based on the structure of M1 AB (ref. 8) , and the B repeats, S region and the initial few residues of the C repeats were modelled based on the structure of M1 BC1 from M1 BC1 -FgD. For C-terminal portions of M1 for which no structural information exists, an a-helical dimeric coiled coil was modelled. Fibrinogen was modelled using the structure of chicken fibrinogen 41 , which has been determined to a higher resolution limit than human fibrinogen 21 . The human and chicken fibrinogen structures show a similar organization, with some flexibility between the FgD portions due to a bend in the central fragment E portion. The initial M1-fibrinogen model, which has intact M1 at the centre of a cross-like structure formed by four fibrinogen molecules, was enlarged as follows. Because each of the four fibrinogen molecules has a second binding site for M1, M1 was modelled at these second sites based on the structure of M1 BC1 -FgD. Furthermore, because M1 binds four fibrinogen molecules, three more fibrinogen molecules were modelled at these second sites based on the structure of M1 BC1 -FgD. This procedure was carried on iteratively to yield the model of the M1-fibrinogen network. Similar procedures were carried out for M1 mutants. Co-precipitation assays. Ten micrograms of wild-type or variant M1 proteins were mixed with 20 mg of FgD in 50 ml of binding buffer (300 mM NaCl, 50 mM sodium phosphate buffer, pH 8.0, 50 mM imidazole, 0.1% (v/v) Triton X-100) at 37 uC for 30 min. Twenty microlitres of Ni 21 -NTA agarose beads were equilibrated in binding buffer and then added to the protein mix and incubated for 30 min at 37 uC under agitation. The beads were washed three times in 200 ml of binding buffer and eluted by boiling the beads for 5 min in non-reducing 53 SDS-PAGE sample loading buffer. Fractions corresponding to unbound and bound proteins were resolved by non-reducing SDS-PAGE.
A similar procedure was used for human IgG Fc fragment (Calbiochem), except for the following changes: 25 mg of M1 or M1*-R protein and 100 mg of Fc were mixed; this mixture was added to 50 ml of equilibrated Ni 21 -NTA agarose beads; washes were 1 ml each; and reducing SDS-PAGE sample loading buffer was used. Heparin binding protein immunoblot. Human neutrophils were purified from healthy donors blood using the PolymorphPrep system (Axis-Shield). Thirteen million neutrophils were incubated with 86 mg ml 21 wild-type or variant M1 protein at 37 uC for 30 min. After centrifugation, the supernatants were resolved on a 12% SDS-PAGE reducing gel and transferred to a PVDF membrane for immunoblotting. Recombinant human heparin binding protein (HBP) (R&D Systems) was used as a reference. The membrane was blocked with Tris buffered saline containing 5% non-fat milk or 5% bovine serum albumin (BSA). HBP was detected using either a primary rabbit anti-human-HBP polyclonal antibody (Sigma) or a mouse anti-human-HBP monoclonal antibody (R&D), peroxidaseconjugated secondary antibodies (Santa Cruz), and the ECL system (Pierce). Electron microscopy. Mixtures containing 10 mg of M proteins and 100 mg of human fibrinogen (Calbiochem) were incubated at 37 uC for 15 min before being ARTICLE RESEARCH
